Recent review on medical treatment of thyroid disease

Kyeong Hye Park, Eunjig Lee

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Thyroid disorder is a common disease. Graves' disease is the most frequent cause of thyrotoxicosis and pharmacological treatment is current trends worldwide. Because of the severe adverse effects of propylthiouracil, methimazole or carbimazole should be selected as the drug of choice except for special situations such as women in the first trimester of pregnancy, thyroid storm, or in patients with severe side effects to methimazole. Treatment should continue for 12 to 18 months, but duration can be adjusted depending on the patient. For hypothyroidism, synthetic levothyroxine is the mainstay of treatment. In order to avoid overtreatment, the dosage of levothyroxine should be determined in consideration of the patient's age, sex, bodyweight, general condition, and comorbidities. In subclinical hypothyroidism, thyroid hormone replacement is suggested in patients with thyroid stimulating hormone concentrations >10 mIU/L. For non-elderly patients with high titers of thyroid autoantibodies, patients with dyslipidemia, pregnant patients, and women with infertility or ovulatory dysfunction, treatment with levothyroxine can be considered.

Original languageEnglish
Pages (from-to)1207-1214
Number of pages8
JournalJournal of the Korean Medical Association
Volume55
Issue number12
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Thyroid Diseases
Thyroxine
Methimazole
Hypothyroidism
Therapeutics
Thyroid Gland
Carbimazole
Thyroid Crisis
Propylthiouracil
Thyrotoxicosis
Graves Disease
Thyrotropin
First Pregnancy Trimester
Dyslipidemias
Thyroid Hormones
Autoantibodies
Infertility
Comorbidity
Pregnant Women
Pharmacology

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{a16d4fea7511419bbb906e01d251b428,
title = "Recent review on medical treatment of thyroid disease",
abstract = "Thyroid disorder is a common disease. Graves' disease is the most frequent cause of thyrotoxicosis and pharmacological treatment is current trends worldwide. Because of the severe adverse effects of propylthiouracil, methimazole or carbimazole should be selected as the drug of choice except for special situations such as women in the first trimester of pregnancy, thyroid storm, or in patients with severe side effects to methimazole. Treatment should continue for 12 to 18 months, but duration can be adjusted depending on the patient. For hypothyroidism, synthetic levothyroxine is the mainstay of treatment. In order to avoid overtreatment, the dosage of levothyroxine should be determined in consideration of the patient's age, sex, bodyweight, general condition, and comorbidities. In subclinical hypothyroidism, thyroid hormone replacement is suggested in patients with thyroid stimulating hormone concentrations >10 mIU/L. For non-elderly patients with high titers of thyroid autoantibodies, patients with dyslipidemia, pregnant patients, and women with infertility or ovulatory dysfunction, treatment with levothyroxine can be considered.",
author = "Park, {Kyeong Hye} and Eunjig Lee",
year = "2012",
month = "12",
day = "1",
doi = "10.5124/jkma.2012.55.12.1207",
language = "English",
volume = "55",
pages = "1207--1214",
journal = "Journal of the Korean Medical Association",
issn = "1975-8456",
publisher = "Korean Medical Association",
number = "12",

}

Recent review on medical treatment of thyroid disease. / Park, Kyeong Hye; Lee, Eunjig.

In: Journal of the Korean Medical Association, Vol. 55, No. 12, 01.12.2012, p. 1207-1214.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Recent review on medical treatment of thyroid disease

AU - Park, Kyeong Hye

AU - Lee, Eunjig

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Thyroid disorder is a common disease. Graves' disease is the most frequent cause of thyrotoxicosis and pharmacological treatment is current trends worldwide. Because of the severe adverse effects of propylthiouracil, methimazole or carbimazole should be selected as the drug of choice except for special situations such as women in the first trimester of pregnancy, thyroid storm, or in patients with severe side effects to methimazole. Treatment should continue for 12 to 18 months, but duration can be adjusted depending on the patient. For hypothyroidism, synthetic levothyroxine is the mainstay of treatment. In order to avoid overtreatment, the dosage of levothyroxine should be determined in consideration of the patient's age, sex, bodyweight, general condition, and comorbidities. In subclinical hypothyroidism, thyroid hormone replacement is suggested in patients with thyroid stimulating hormone concentrations >10 mIU/L. For non-elderly patients with high titers of thyroid autoantibodies, patients with dyslipidemia, pregnant patients, and women with infertility or ovulatory dysfunction, treatment with levothyroxine can be considered.

AB - Thyroid disorder is a common disease. Graves' disease is the most frequent cause of thyrotoxicosis and pharmacological treatment is current trends worldwide. Because of the severe adverse effects of propylthiouracil, methimazole or carbimazole should be selected as the drug of choice except for special situations such as women in the first trimester of pregnancy, thyroid storm, or in patients with severe side effects to methimazole. Treatment should continue for 12 to 18 months, but duration can be adjusted depending on the patient. For hypothyroidism, synthetic levothyroxine is the mainstay of treatment. In order to avoid overtreatment, the dosage of levothyroxine should be determined in consideration of the patient's age, sex, bodyweight, general condition, and comorbidities. In subclinical hypothyroidism, thyroid hormone replacement is suggested in patients with thyroid stimulating hormone concentrations >10 mIU/L. For non-elderly patients with high titers of thyroid autoantibodies, patients with dyslipidemia, pregnant patients, and women with infertility or ovulatory dysfunction, treatment with levothyroxine can be considered.

UR - http://www.scopus.com/inward/record.url?scp=84872134839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872134839&partnerID=8YFLogxK

U2 - 10.5124/jkma.2012.55.12.1207

DO - 10.5124/jkma.2012.55.12.1207

M3 - Review article

AN - SCOPUS:84872134839

VL - 55

SP - 1207

EP - 1214

JO - Journal of the Korean Medical Association

JF - Journal of the Korean Medical Association

SN - 1975-8456

IS - 12

ER -